Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool below to find open protocols for your type of cancer. To learn more about eligibility and participation call 877-789-6100.

Search by conditions: 

Click a protocol # to view extended details on a particular clinical trial.

Protocol #DescriptionPhase
09-307A Phase I Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases Are Linked to Disease Pathophysiology  (View details on I
12-466Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on II
13-059SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors  (View details on II
3 clinical trials listed.

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.